Literature DB >> 10520009

Acute lymphoblastic leukaemia occurring as second malignancy: report of the GIMEMA archive of adult acute leukaemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto.

L Pagano1, A Pulsoni, M E Tosti, L Annino, A Mele, A Camera, B Martino, C Guglielmi, R Cerri, E Di Bona, R Invernizzi, C Castagnola, R Bassan, L Mele, G Todeschini, G Leone, F Mandelli.   

Abstract

Between July 1992 and June 1996, 901 new cases of adult acute lymphoblastic leukaemia were recorded in the GIMEMA Archive of Adult Acute Leukaemia; 21 of them (2.3%) had a previous primary malignancy (PM). We found that secondary acute lymphoblastic leukaemia cases (sALL) presented with older age, a high incidence of pre-pre-B immunophenotype and a significantly higher prevalence of cancer among relatives compared to de novo ALL. The leukaemogenic activity of the cytotoxic drugs employed for the treatment of PM may have played a potential role in only a proportion of patients, opening the possibility that some sALL patients may have developed two or more malignancies due to individual predisposing factors.

Entities:  

Mesh:

Year:  1999        PMID: 10520009     DOI: 10.1046/j.1365-2141.1999.01636.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  24 in total

1.  Therapy-related ALL: cytogenetic features and hematopoietic cell transplantation outcome.

Authors:  I Aldoss; A Dagis; J Palmer; S Forman; V Pullarkat
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

2.  Therapy-related acute lymphoblastic leukemia.

Authors:  Josep-Maria Ribera
Journal:  Haematologica       Date:  2018-10       Impact factor: 9.941

Review 3.  A focused review of hematopoietic neoplasms occurring in the therapy-related setting.

Authors:  Liping Zhang; Sa A Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

4.  Secondary Acute Lymphoblastic Leukemia after Hodgkin's Lymphoma or a Coincidental Association of Two Hematological Malignancies?

Authors:  Mihaela Tevet; Cornel Dragan; Carmen Saguna; Doina Barbu; Anca Roxana Lupu
Journal:  Maedica (Buchar)       Date:  2013-09

5.  Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?

Authors:  Guilin Tang; Zhuang Zuo; Deborah A Thomas; Pei Lin; Dingsheng Liu; Ying Hu; Hagop M Kantarjian; Carlos Bueso-Ramos; L Jeffrey Medeiros; Sa A Wang
Journal:  Haematologica       Date:  2011-12-29       Impact factor: 9.941

6.  Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor.

Authors:  Hyoeun Shim; Hyun-Sook Chi; Seongsoo Jang; Eul-Ju Seo; Chan-Jeoung Park; Jung-Hee Lee; Je-Hwan Lee; Kyoo-Hyung Lee
Journal:  Korean J Hematol       Date:  2010-09-30

7.  Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.

Authors:  Matthew M Hsieh; Melissa Bonner; Francis John Pierciey; Naoya Uchida; James Rottman; Laura Demopoulos; Manfred Schmidt; Julie Kanter; Mark C Walters; Alexis A Thompson; Mohammed Asmal; John F Tisdale
Journal:  Blood Adv       Date:  2020-05-12

8.  Acute lymphoblastic leukemia following temozolomide treatment in a patient with glioblastoma: A case report and review of the literature.

Authors:  Pengfei Liu; Peiwen Li; Ting Lei; Limei Qu; Haiyan Huang; Qingchun Mu
Journal:  Oncol Lett       Date:  2018-04-04       Impact factor: 2.967

Review 9.  Secondary acute lymphoblastic leukemia, a retrospective analysis from Washington University and meta-analysis of published data.

Authors:  Francesca Ferraro; Feng Gao; Keith Stockerl-Goldstein; Peter Westervelt; John F DiPersio; Armin Ghobadi
Journal:  Leuk Res       Date:  2018-07-31       Impact factor: 3.156

10.  Biologic features and treatment outcome of secondary acute lymphoblastic leukemia--a review of 101 cases.

Authors:  R Shivakumar; W Tan; G E Wilding; E S Wang; M Wetzler
Journal:  Ann Oncol       Date:  2008-05-07       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.